Expand All

Representative Matters

  • We represented a global leader in the immunodiagnostics market and an international player in the in vitro diagnostics market in the acquisition of a product line for the diagnosis of HIV, HCV and HBV infections from Abbott Diagnostics. Abbott was represented by Baker & McKenzie.
  • We represented the Special Independent Committee of the Board of Directors of a New York Stock Exchange-listed pharmaceutical company in considering the company’s strategic alternatives which resulted in a merger agreement valued at U.S. $346 million with Nycomed, headquartered in Zurich, Switzerland. Deutsche Bank Securities Inc. acted as advisor to our client. Nycomed was represented by Dorsey & Whitney and Morgan Stanley was the financial advisor.
  • We represented an international engines and transportation manufacturing unit of a European-based automobile manufacturer in the acquisition of Chrysler’s Tritec Motors plant for $150 million including R&D costs. Chrysler was represented by Schulte Roth & Zabel.
  • We advised a major international conglomerate and several of its holdings, headquartered in Italy, in numerous transactions:
    • A $116 million acquisition of Carbomedics, a manufacturer of mechanical and biological heart valves, from Zurich-based Centerpulse (NYSE:CEP).
    • The acquisition of COBE CV, an international cardiovascular device business for $267 million from Gambro AB, a Swedish medical device company pursuant to a managed sale auction; we simultaneously sold the Heart Lung Machine Division to Baxter to obtain U.S. antitrust clearance.
    • The purchase of the Shiley Cardiovascular Division, with operations in 17 countries, from Pfizer Inc. for $280 million.
    • The sale of its diagnostic business to American Standard for $250 million including a 51% interest in INCSTAR, a Nasdaq-listed company.
  • We have advised a large German conglomerate, on an ongoing basis, on corporate governance and compliance issues and on potential acquisitions, joint ventures and joint marketing on such expansion projects and on a more than $1 billion cross-border managed auction process to purchase additional product lines.
  • We represented an Italian specialty chemical public company in the formation of a Canadian specialty chemical joint venture introducing a new technology into the North American pulp and paper industry.
  • We represented a Nasdaq-listed life sciences company in its strategic alliance with a New York Stock Exchange-listed international pharmaceutical company. The strategic alliance involved the creation of a joint venture company with technology licenses by each joint venture party and a significant investment in our client by the New York Stock Exchange-listed international pharmaceutical company.
  • We represented a chemical company in its sale of a New Jersey chemical plant to a Canadian conglomerate.
  • We represented a New York Stock Exchange-listed plastics company in its purchase of a polyvinyl chloride plant in Burlington, New Jersey. The seller was Occidental Petroleum. Subsequently, we sold the plant to a Japanese company in connection with a re-positioning within the industry.



Practice Members